544 related articles for article (PubMed ID: 27722984)
1. Clinicopathological Features of a Series of 27 Cases of Post-Denosumab Treated Giant Cell Tumors of Bones: A Single Institutional Experience at a Tertiary Cancer Referral Centre, India.
Rekhi B; Verma V; Gulia A; Jambhekar NA; Desai S; Juvekar SL; Bajpai J; Puri A
Pathol Oncol Res; 2017 Jan; 23(1):157-164. PubMed ID: 27722984
[TBL] [Abstract][Full Text] [Related]
2. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
3. Response evaluation of giant-cell tumor of bone treated by denosumab: Histogram and texture analysis of CT images.
Yi J; Lee YH; Kim SK; Kim SH; Song HT; Shin KH; Suh JS
J Orthop Sci; 2018 May; 23(3):570-577. PubMed ID: 29429890
[TBL] [Abstract][Full Text] [Related]
4. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
Ud Din N; Umer M; Park YK
Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
[No Abstract] [Full Text] [Related]
5. [Clinical, radiologic and pathologic features of giant cell tumor of bone treated with denosumab].
Gong LH; Liu WF; Ding Y; Zhang W; Yang YK; Yu F; Wong GQ; Huang XY; Niu XH
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):449-454. PubMed ID: 29886590
[No Abstract] [Full Text] [Related]
6. Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.
Mukaihara K; Suehara Y; Kohsaka S; Akaike K; Tanabe Y; Kubota D; Ishii M; Fujimura T; Kazuno S; Okubo T; Takagi T; Yao T; Kaneko K; Saito T
PLoS One; 2016; 11(2):e0148401. PubMed ID: 26863138
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
8. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
Rutkowski P; Gaston L; Borkowska A; Stacchiotti S; Gelderblom H; Baldi GG; Palmerini E; Casali P; Gronchi A; Parry M; Campanacci DA; Scoccianti G; Wagrodzki M; Ferrari S; Dijkstra S; Pieńkowski A; Grimer R
Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420
[TBL] [Abstract][Full Text] [Related]
9. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
Rutkowski P; Ferrari S; Grimer RJ; Stalley PD; Dijkstra SP; Pienkowski A; Vaz G; Wunder JS; Seeger LL; Feng A; Roberts ZJ; Bach BA
Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
[TBL] [Abstract][Full Text] [Related]
10. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
Roitman PD; Jauk F; Farfalli GL; Albergo JI; Aponte-Tinao LA
Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
[TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
[TBL] [Abstract][Full Text] [Related]
12. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
Agarwal MG; Gundavda MK; Gupta R; Reddy R
Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
Tariq MU; Umer M; Khan Z; Saeed J; Siddiqui MA; Din NU
Ann Diagn Pathol; 2020 Apr; 45():151479. PubMed ID: 32088577
[TBL] [Abstract][Full Text] [Related]
14. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases.
Deveci MA; Paydaş S; Gönlüşen G; Özkan C; Biçer ÖS; Tekin M
Acta Orthop Traumatol Turc; 2017 Jan; 51(1):1-6. PubMed ID: 27784623
[TBL] [Abstract][Full Text] [Related]
17. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
[TBL] [Abstract][Full Text] [Related]
18. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
[TBL] [Abstract][Full Text] [Related]
19. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Characterization of Giant Cell Tumor of Bone Treated With Denosumab: Support for Osteoblastic Differentiation.
Kerr DA; Brcic I; Diaz-Perez JA; Shih A; Wilky BA; Pretell-Mazzini J; Subhawong TK; Nielsen GP; Rosenberg AE
Am J Surg Pathol; 2021 Jan; 45(1):93-100. PubMed ID: 32773532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
